Sintilimab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Effect of Drugs
Conditions
Effect of Drugs
Trial Timeline
Aug 23, 2017 → Feb 28, 2020
NCT ID
NCT03228836About Sintilimab
Sintilimab is a phase 2 stage product being developed by Innovent Biologics for Effect of Drugs. The current trial status is completed. This product is registered under clinical trial identifier NCT03228836. Target conditions include Effect of Drugs.
What happened to similar drugs?
2 of 4 similar drugs in Effect of Drugs were approved
Approved (2) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05594381 | Phase 2 | UNKNOWN |
| NCT05024968 | Phase 2 | Completed |
| NCT04400851 | Phase 1 | UNKNOWN |
| NCT04220944 | Phase 1 | Active |
| NCT03812549 | Phase 1 | Completed |
| NCT03228836 | Phase 2 | Completed |
Competing Products
20 competing products in Effect of Drugs